(Q36468076)

English

The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 August 2017

The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer (English)

1 reference

Europe PubMed Central

14 August 2017

0 references

1 reference

based on heuristic

inferred from title

0 references

author name string

Bronchud MH

1

1 reference

Europe PubMed Central

14 August 2017

Howell A

2

1 reference

Europe PubMed Central

14 August 2017

Crowther D

3

1 reference

Europe PubMed Central

14 August 2017

Hopwood P

4

1 reference

Europe PubMed Central

14 August 2017

Souza L

5

1 reference

Europe PubMed Central

14 August 2017

Dexter TM

6

1 reference

Europe PubMed Central

14 August 2017

language of work or name

0 references

publication date

1 July 1989

1 reference

Europe PubMed Central

14 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

14 August 2017

60

1 reference

Europe PubMed Central

14 August 2017

121-125

1 reference

Europe PubMed Central

14 August 2017

1

1 reference

Europe PubMed Central

14 August 2017

https://scigraph.springernature.com/pub.10.1038/bjc.1989.234

0 references

High-dose doxorubicin: an exploration of the dose-response curve in human neoplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247341

30 September 2017

A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247341

30 September 2017

The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247341

30 September 2017

Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247341

30 September 2017

The role of high-dose chemotherapy with autologous bone marrow transplantation in the treatment of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247341

30 September 2017

Dose-response in the treatment of breast cancer: a critical review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247341

30 September 2017

Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247341

30 September 2017

Assessment of response to therapy in advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247341

30 September 2017

Amputation and adriamycin in primary osteosarcoma: a 5-year report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247341

30 September 2017

A phase I-II study of intensive-dose adriamycin for advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247341

28 June 2018

Quality of life in cancer trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247341

28 June 2018

Criteria associated with destruction of leukemia and solid tumor cells in animals

1 reference

https://pubmed.ncbi.nlm.nih.gov/2478178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adriamycin therapy for advanced ovarian carcinoma recurrent after chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/2478178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose: a critical factor in cancer chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/2478178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/2478178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-response is alive and well

1 reference

https://pubmed.ncbi.nlm.nih.gov/2478178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1989.234

1 reference

Europe PubMed Central

14 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36468076&oldid=1518429687"